Podcasts about fsgs

Neil Haley welcomes Hall of Fame basketball legend Alonzo Mourning and LaVarne Addison Burton, CEO of the American Kidney Fund (AKF), to discuss APOL1-mediated kidney disease (AMKD). Alonzo shares his personal experience with kidney disease, emphasizing the importance of early detection, proactive healthcare, genetic testing, and open communication with doctors—especially for people of color, who are at a higher risk for AMKD.1. Understanding AMKD:APOL1-mediated kidney disease is caused by specific genetic mutations in the APOL1 gene.Higher risk among individuals with African, Afro-Caribbean, Latino/Latina, and Black American heritage.2. Alonzo Mourning's Personal Story:Diagnosed following abnormal blood tests and fatigue during the 2000 Olympics.Initial symptoms included swelling in legs and fatigue.Eventually diagnosed with focal segmental glomerulosclerosis (FSGS), a form of AMKD.Received a kidney transplant in 2003, returned to professional basketball, and won an NBA championship in 2006.3. Importance of Early Detection:Recognizing and not ignoring symptoms can prevent or delay kidney failure.Encourages listeners to be proactive and visit doctors regularly.4. Genetic Testing and Medical Care:Genetic testing is crucial to identifying AMKD.Encourages seeking multiple medical opinions for accurate diagnosis and effective care.5. Addressing Medical Mistrust:Alonzo highlights the historical mistrust of healthcare in communities of color.Emphasizes importance of overcoming this mistrust to ensure proper care.6. Awareness Initiatives:Second annual AMKD Awareness Day observed on April 29th.AKF providing comprehensive resources and education via their website.“Health is wealth. If you don't have your health, you don't have anything.” – Alonzo Mourning“Early detection can significantly improve outcomes and slow disease progression.” – LaVarne Addison BurtonAmerican Kidney Fund Website: kidneyfund.org/amkdEmpower Forward Website: empowerforwardtogether.comAlonzo Mourning: Hall of Fame Basketball Player, Spokesperson for Vertex Pharmaceuticals.LaVarne Addison Burton: President and CEO, American Kidney Fund.Key Discussion Points:Memorable Quotes:Resources and Information:Connect with Alonzo Mourning and AKF:

Liverpool skal nå ha blitt enige med Bayern Leverkusen om en overgang for Florian Wirtz, ifølge tungvektere som Paul Joyce fra The Times og David Ornstein fra The Athletic. Summen som er avtalt kan potensielt ende på 116 millioner pund. Der det er 100 millioner garantert for Leverkusen, og 16 millioner i mulige bonuser.Dette er soleklar klubbrekord som den dyreste signeringen i Liverpools historie, men vil også bli britisk overgangsrekord.Denne uken samlet vi nesten hele panelet av Pausepraten til en spesialepisode. Der ble naturligvis rekordovergangen et tema. Hele episoden vil vi legge ut seinere, men her har vi tatt med noe av det som ble sagt om denne signeringen.For er det riktig å bruke så mye penger på én spiller? Og er dette den største signeringen i FSGs historie? Med i panelet er Arve Vassbotten, Mari Lunde, Tore Hansen, Arild Skjæveland, Stefan Fosse og Jens Bessesen. Hosted on Acast. See acast.com/privacy for more information.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for May 5- 11, 2025: FDA Accepts Sparsentan (Filspari) sNDA for Focal Segmental Glomerulosclerosis The FDA will review Travere Therapeutics' application for full approval of sparsentan in FSGS, with an advisory committee meeting planned ahead of a January 2026 decision. FDA Accepts BioCryst's NDA for Berotralstat Oral Granules in Children With HAE The FDA is evaluating berotralstat oral granules for pediatric hereditary angioedema, which could become the first oral preventive therapy for children under 12. SURMOUNT-5: Tirzepatide (Zepbound) Proves Benefit over Semaglutide (Wegovy) for Obesity Tirzepatide demonstrated superior weight loss outcomes compared with semaglutide in the SURMOUNT-5 trial for patients with obesity. Crinecerfont Reduces Steroid Use for Pediatric CAH in Phase 3 Analysis Crinecerfont lowered steroid requirements while maintaining hormone control in children with classic congenital adrenal hyperplasia, regardless of baseline characteristics. Type 1 Diabetes Diagnosed in Adulthood Heightens Cardiovascular Risk Adults diagnosed with type 1 diabetes face increased cardiovascular and all-cause mortality risks, regardless of age at diagnosis, according to long-term national data.

Darren is the TikTok Kidney Warrior and helps people by filming videos about CKD symptoms. He is the early stages after a stroke and a diagnosis of FSGS so is determined to raise awareness…..Disclaimer: All views, information or opinions expressed in this podcast series are solely my own.The primary purpose of this podcast series is to inform, but it does not constitute medical or other professional advice or services. Please seek advice from your own medical teams regarding your own health.

As our understanding of APOL1-Mediated Kidney Disease (AMKD) grows, so does the need for greater awareness. National APOL1-Mediated Kidney Disease (AMKD) Awareness Day is observed annually on the last Tuesday of April.  In this episode of Kidney Transplant Conversations, we share an inspiring story of resilience, advocacy, and hope. Sharron Rouse opens up about her personal journey with kidney disease — a journey that began with a diagnosis of lupus nephritis, only to later discover she was actually battling FSGS (focal segmental glomerulosclerosis), a condition sometimes linked to the APOL1 gene variant that is found in around 35% of people of African ancestry.  In a heartfelt conversation with host Rolf Taylor, Sharron discusses the shock of her diagnosis, the challenges of navigating unclear answers, and the life-changing gift of a kidney transplant from her sister. As the founder of Kindness for Kidneys International, Sharron is now a tireless advocate, raising awareness about the genetic factors influencing kidney health. She emphasizes the importance of early diagnosis, the critical role of research into APOL1-related kidney disease, and the urgent need for greater awareness in communities of African descent. Tune in to hear how Sharron's story offers hope to kidney warriors everywhere, highlights the life-saving potential of genetic testing, and makes a powerful case for early intervention. This episode is both inspiring and a call to action for greater education, early screening, and community empowerment. Kindness for Kidneys Website: https://www.kindnessforkidneys.org/ APOL1-Mediated Kidney Disease (AMKD) Awareness Day: https://www.kidneyfund.org/amkd-day-proclamation  Should I get tested for the APOL1 gene? https://www.kidney.org/kidney-topics/apol1-mediated-kidney-disease-amkd  (c) Project Advocacy 2025      

In this powerful episode of Diary of a Kidney Warrior Podcast, host Dee Moore is joined by Nick Palmer, who shares his extraordinary journey of living with chronic kidney disease (CKD) and focal segmental glomerulosclerosis (FSGS). Diagnosed at just 19 years old, Nick opens up about navigating the complex realities of kidney disease as a young adult—balancing university, a demanding career, and the emotional toll of a condition that would require multiple transplants and ongoing dialysis.   With unflinching honesty, Nick reflects on his decision to decline a third kidney transplant and instead embrace home nocturnal dialysis—a choice that profoundly improved his quality of life, restored his sense of independence, and helped him reclaim control of his health. He discusses the impact of this decision on his mental well-being, family life, and career, and how it ultimately allowed him to thrive in ways he never expected.   Nick's story challenges traditional narratives around kidney treatment, shining a light on the importance of patient choice, education, and mental health advocacy in chronic illness care. This episode is a must-listen for anyone navigating kidney disease, healthcare professionals, or anyone seeking inspiration from a story of resilience and informed self-advocacy.   Key topics include: Living with FSGS and the impact of early diagnosis The emotional and physical toll of dialysis in early adulthood The recurrence of FSGS post-transplant Choosing nocturnal dialysis and the profound benefits for quality of life Mental health, self-advocacy, and redefining what it means to live fully with CKD   Follow Diary of a Kidney Warrior:  

Jaime Albright Henighan shares her family's journey after two of her sons, Joshua and Jorden, were diagnosed with a rare genetic kidney disease called APOL1-mediated FSGS (Focal Segmental Glomerulosclerosis).   Jaime's story highlights the importance of early detection, education, and advocacy for families navigating this challenging condition. She discusses her partnership with Nephcure, a patient advocacy organization, and her mission to raise awareness about FSGS, especially among individuals of West African descent, who are at higher risk due to the APOL1 gene mutation.   Topics Covered: What is FSGS?: Understanding APOL1-mediated FSGS and its impact on kidney health. The Family's Journey: How high blood pressure led to Joshua's diagnosis, and the shock of discovering Jorden had the same condition. The Role of Genetics: Why individuals of West African descent are at greater risk and the importance of genetic awareness. Early Detection: How identifying symptoms early has helped Jaime's sons manage their health. Advocacy and Education: Jaime's work with Nephcure and her efforts to raise awareness globally, including in Ghana. Parenting Through Challenges: Jaime's emotional journey as a mother and her advice for other parents navigating rare diseases.   Key Moments: Jaime explains how her family discovered FSGS and the challenges they faced in obtaining a diagnosis. Insights into the genetic factors behind APOL1-mediated FSGS and its prevalence in specific populations. Advocacy efforts to educate families and healthcare providers about the disease.   Guest Bio: Jaime is a wife and mother of six. Her family resides in Alpharetta, GA. She is also a Forensic Interviewer and Podcast Producer at Tenderfoot TV. In 2021, her seemingly healthy 17 year old son, Joshua, was randomly diagnosed with high blood pressure. This led to additional testing and a diagnosis of Focal Segmental Glomerulosclerosis (FSGS), a rare genetic kidney disease. Later that year, her 25 year old son, Jorden, was also diagnosed with FSGS. This was shocking to the Albright Henighan family. How could they be at high risk of a disease that they had never heard of? They connected with Nephcure, a patient advocacy organization, for support and resources. They learned that 1 in 8 people of West African descent are at risk of APOL1 mediated FSGS due to a genetic mutation. Thanks to early detection, her sons are stable today but this is a rare outcome for FSGS patients due to a lack of education and barriers in the medical community. They decided to share their story across the United States and even in Ghana. Their goal is to educate and empower others. If caught early, there are medical interventions and clinical research trials that can save native kidneys and lives. There is hope for FSGS patients.   Resources Mentioned: Nephcure Kidney International: Advocacy and support for families affected by kidney diseases. Information on APOL1-mediated FSGS and genetic testing. Tips for recognizing early symptoms of kidney disease.   Connect with Us:  Stay tuned for the next new episode of “It Happened To Me”! In the meantime, you can listen to our previous episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “It Happened To Me”.    “It Happened To Me” is created and hosted by Cathy Gildenhorn and Beth Glassman. DNA Today's Kira Dineen is our executive producer and marketing lead. Amanda Andreoli is our associate producer. Ashlyn Enokian is our graphic designer.   See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, ItHappenedToMePod.com. Questions/inquiries can be sent to ItHappenedToMePod@gmail.com. 

Welcome to another episode of On the Couch, the podcast series where we chat with brokers, CEOs, and fund managers to give you valuable insights into the investing world.In this episode, Henry Jennings is joined by Dr Nina Webster, CEO and Managing Director of Dimerix (ASX: DXB), a clinical-stage biopharmaceutical company working on treatments for inflammatory diseases. With a market cap of $270 million, Dimerix is advancing its proprietary Phase 3 candidate DMX-200 to treat Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease, and is also developing DMX-700 for respiratory disease.Nina has over 30 years of experience in the pharmaceutical industry, with leadership roles across research, development, and commercialisation. She was formerly Commercial Director at Acrux (ASX: ACR), an Australian pharmaceutical company that successfully developed and commercialised multiple products globally. She is also Non-Executive Chairperson for SYNthesis BioVentures and a Non-Executive Director at Linear Clinical Research Limited. Dr Webster holds a Ph.D in Pharmaceutics from Cardiff University, a Bachelor's degree in Pharmacology, a Master's in Intellectual Property Law from Melbourne University, and an Executive MBA from RMIT.Talking Points:Dimerix is focused on developing and commercialising new treatments for inflammatory diseases with poor outcomes. The leading drug candidate is a treatment for a rare kidney disease known as FSGS - what's the nature of this disease and its current treatment?What's changed, and how did DXB come about?DMX-200 is now in a global Phase 3 clinical trial - an update on the trial and when results are expected.The upside from here following DXB's strong run.Are all the eggs in one basket if this trial is not successful? What is Plan B?Three successful commercial deals - how they came together.CEOs shouldn't speculate on future licensing deals, but the US market is always the big one. What interest has there been from US pharma companies?How does what's happening in the US impact Dimerix? Elon Musk has been vocal about the FDA, and with Kennedy in charge, is there extra risk of regulatory slowdowns?NEU as a playbook - Dr Webster previously worked with NEU's CEO at Acrux. Is Dimerix a bona fide Neuren replica?Cash reserves and burn rate - what's the current financial position?Who are Dimerix's biggest shareholders?If the FSGS trial goes well, what happens next? Licensing?What will be the major Dimerix milestones for 2025?A deep dive into Dimerix, the biotech sector, and what's ahead for the company.Listen now to hear the full conversation.Disclaimer: This is general advice only. Please consult your financial adviser before making any investment decisions.If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you.Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals. Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories included the US Food and Drug Administration's (FDA) acceptance of a Biologics License Application (BLA) for a cholesterol-lowering drug, long-term data on a dermatologic treatment for hidradenitis suppurativa, an expanded dosing label for a blinding eye disease treatment, and more! With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of February 09, 2025—let's jump in! Interested in oncology news? Check out The OncFive, from our sister publication OncLive. Top News for Healthcare Providers from the Week of 02/09 1. FDA Accepts Lerodalcibep BLA for LDL-C Reduction in High-Risk Patients The FDA accepted the BLA for lerodalcibep, targeting reductions in low-density lipoprotein cholesterol (LDL-C) levels in patients with or at high risk for atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia. The agency set a Prescription Drug User Fee Act (PDUFA) action date of December 12, 2025, and announced no plans to hold an advisory committee meeting. 2. Travere Therapeutics Plans FSGS Submission for Sparsentan Travere Therapeutics announced its intent to submit a supplemental New Drug Application (sNDA) for sparsentan (Filspari) with the FDA for the treatment of focal segmental glomerulosclerosis (FSGS) at the end of Q1. The announcement arrived soon after the completion of a Type C meeting with the FDA, with the sNDA based on existing data from the Phase 3 DUPLEX and Phase 2 DUET studies. 3. Bimekizumab Long-Term Hidradenitis Suppurativa Data Support Efficacy, Safety Profile Bimekizumab (Bimzelx) was associated with sustained disease control for up to 2 years in patients with hidradenitis suppurativa (HS), according to presentation of long-term data from the BE HEARD trials. Presented at the 14th Conference of the European Hidradenitis Suppurativa Foundation (EHSF), bimekizumab reduced the symptoms of HS, achieved a low rate of flares, and improved health-related quality of life. 4. Rosnilimab Demonstrates Historic Responses for Rheumatoid Arthritis Rosnilimab achieved historic American College of Rheumatology (ACR) and clinical disease activity index (CDAI) low disease activity (LDA) responses in patients with rheumatoid arthritis (RA), according to new Phase 2b findings. A depleter and agonist of PD-1+ T cells, rosnilimab was evaluated in the global 424-patient RENOIR trial for efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with moderate-to-severe RA on background conventional disease-modifying antirheumatic drugs (cDMARDs). 5. FDA Expands Dosing Label for Avacincaptad Pegol for Geographic Atrophy The FDA approved an expanded label for avacincaptad pegol intravitreal solution (IZERVAY) for geographic atrophy (GA), extending the approved dosing beyond 12 months. Announced by Astellas Pharma, the decision comes after the company resubmitted its supplemental New Drug Application (nDA) in December 2024, based on feedback received from the FDA. The company received a Complete Response Letter (CRL) the month prior. See you next week! Editor's note: this was created with the assistance of AI tools. 

Description: WVON radio host Atiba Buchanan built his career on speaking up and speaking out.  When as an otherwise healthy young man he learned he had a silent disease called FSGS, he began to use his voice to advocate for himself and others walking the same path.

EIn this episode of Take a Pain Check, host Natasha introduces Emily Wahl, who bravely shares her journey living with Juvenile Rheumatoid Arthritis (JRA), Sjogren's syndrome, Lupus, Pulmonary Arterial Hypertension, and FSGS. Emily candidly discusses her diagnosis story, recounting childhood experiences with arthritis and the challenges of managing various medications. She reflects on how her health conditions influenced her career choices and relationships, especially during pregnancy. Emily advocates for patients like herself, emphasizing the importance of a supportive care team and sharing coping strategies for the emotional weight of new diagnoses. Additionally, she offers insights into navigating pregnancy with chronic illnesses and provides valuable advice for managing multiple conditions effectively. Join our peer support group here for this month's session in May: https://us02web.zoom.us/meeting/register/tZ0tdemsrj8oHtwosUn8w7ZcwHxdGYZPDEDv#/registration Emily's socials: @healmewholeheartedly www.healmewholeheartedly.com Our socials: Website: ⁠https://www.takeapaincheck.com/⁠ Instagram: ⁠ https://www.instagram.com/takeapaincheck_/ Tiktok: ⁠https://www.tiktok.com/@takeapaincheck?lang=en Facebook: https://www.facebook.com/TakeaPainCheck/ LinkedIn: https://www.linkedin.com/company/take-a-pain-check/?originalSubdomain=ca

Josh Tarnoff joined NephCure as CEO in early 2018, fulfilling a long-held desire to serve the rare disease patient community more closely. He spent more than 30 years working in the pharmaceutical and biotechnology community, moving new therapies closer to reality. Personal connections with NephCure families fuel his passion to achieve NephCure's mission-driven goals, and he always appreciates directly speaking with our community. Josh also has personal insights into renal disease as he was once a patient, likely a result of a snake bite. He lives in Pennsylvania, where he enjoys backpacking — while also trying to avoid further contact with venomous snakes. Click here to learn more about NephCure.  Host: Kent Bresler Producer: Jason Nunez Remember to keep breathing, and don't miss the next amazing episodes of Kent's Kidney Stories!

In this heartwarming episode, Kent Bresler sits down with Jennifer Cramer-Miller, author of "Incurable Optimist: Living with Illness and Chronic Hope." Jennifer shares her profound journey as a fellow FSGS patient who has navigated the tumultuous waters of dialysis, multiple transplants, and the relentless pursuit of hope and joy amidst chronic illness. Their conversation explores the emotional landscape of kidney disease, the power of acceptance, and the miracles that unfold when people show up for one another with acts of profound kindness. Jennifer's story is a testament to the strength found in vulnerability and the beauty that emerges from life's toughest challenges. As they delve into the five parts of her book—failing, wishing, receiving, accepting, and unfailing—listeners are invited to reflect on their own journeys and the interconnectedness that binds us all in times of adversity. Jennifer's resilience and optimism offer a beacon of light for those navigating similar paths, reminding us that even in the face of an incurable condition, one can live with 'chronic hope.' For those touched by Jennifer's story or seeking support in their own kidney health journey, Kent encourages reaching out for the community and guidance. Tune in to this episode for an enriching conversation that affirms life's capacity for joy, even amidst its most profound challenges. Host: Kent Bresler Producer: Jason Nunez Remember to keep breathing, and don't miss the next amazing episodes of Kent's Kidney Stories! "Incurable Optimist: Living with Illness and Chronic Hope" by Jennifer Cramer-Miller is available in print, ebook, and audiobook formats for those who prefer listening to reading. Visit JenniferCramerMiller.com to connect with her directly.

Interviewing Marcelo Pena The expression “making up for lost time” is used in many different situations. Buckets lists. To-do lists. Rekindled friendships and long-lost loves. But what if you spent decades of your life – from childhood in adulthood – feeling sick, and unable to live a fulfilling life? And what if, after living that way all those years, you suddenly found something that could help you feel better, be more independent, and enjoy the things you'd been missing? This is a quick glimpse into the life of Marcelo*, a 35-year-old home hemodialysis patient from North Carolina doing everything in his power to make up for the time he lost to end stage renal disease. Childhood Interrupted Marcelo started his life like most kids. He was happy and healthy, enjoyed playing with his cousins, and attended grade school in his home city of Chicago. At 10-years old he got sick and went to his doctor to figure out what was going on. After some testing, they found blood and protein in his urine and immediately ordered a biopsy. Then, a short time later, on his eleventh birthday, he was diagnosed with Focal Segmental glomerulosclerosis (FSGS). FSGS is a disease that causes scar tissue build-up on the kidneys and can permanently impair their function. When Marcelo was 13 it was determined that his kidney function had declined and was now at a point where a decision had to be made, receive a transplant or start dialysis. That's when Marcelo's mother offered her own kidney. “My mother was my hero,” says Marcelo. “She gave me life twice. She said, ‘I'll give him one of my kidneys and hopefully this will just all be a memory.'” Sadly the kidney Marcelo received only lasted around 6 months, once again due to complications from FSGS and he had to start dialysis. First it was peritoneal dialysis (PD), which was effective but left Marcelo with what felt like almost no time for himself. “Back then the machines were different, and I had to dialyze up to 12 hours straight,” Marcelo explains. “That was my life for three years. I felt like no one was going through what I was going through. I felt alone for a very long time.” In his late teens, Marcelo learned he could not continue PD and doctors prescribed in-center hemodialysis (ICHD) as the only alternative. That began a 16-year journey as an in-center patient. During that time, Marcelo experienced other health problems that almost turned deadly. And even though dialysis therapy kept him alive, he saw it as taking away from his quality of life. “It was almost like I was sentenced to dialysis,” Marcelo says. “For 16 years it was a Monday therapy session, and then I'd feel tired all day and into Tuesday. When I felt somewhat OK, I'd go out for a walk or something, but the next day I had to start all over again. It felt like dialysis, dialysis, dialysis, nonstop. I was so depressed and on all kinds of medications and antidepressants, just trying to cope.” It wasn't until his thirties that Marcelo learned of another alternative to ICHD. A nurse at his clinic began telling him about more frequent home hemodialysis. Marcelo was in a dark place, and he needed a change, so he decided to try it. After his training was complete, he was able to do his therapy at home for the first time in decades. In addition to the physical changes Marcelo has seen and felt, he's found several ways to make up for all those lost years. Since starting on HHD he has taken his NxStage machine to Disney World, Nashville, North Carolina, and Pennsylvania. He hosts a kidney health-based radio show on iHeart Radio and has an established presence on social media. He's learning to play ukulele, writing a book, and is certified in yoga and meditation instruction. He also has a new best friend – a Boston Terrier named Benjamin! SEEYA NeXt time! To send us a voicemail to ask a question, make a comment or to tell us about your medical journey click on this link! https://podcasters.spotify.com/pod/show/blindchickliving/message --- Send in a voice message: https://podcasters.spotify.com/pod/show/blindchickliving/message

Every so often, we cross paths with a story so powerful, it redefines the essence of resilience and hope; Blake's journey is one such saga. Born with underdeveloped kidneys and later diagnosed with FSGS, Blake's tale is a testament to enduring the highs and lows of chronic illness with unwavering spirit. His path has been paved with challenges, from the heartwarming generosity of receiving kidney transplants from both parents to grappling with the harsh side effects of lifelong medications like prednisone. Throughout this episode, Blake opens his heart to us, sharing the personal victories and the formidable obstacles of his condition.Imagine facing a life where your daily routine is dictated by the meticulous management of anti-rejection drugs, and where your childhood dreams are set aside due to the limitations of a relentless disease. Blake's narrative is not just about the tribulations of his health; it's also a journey through personal transformation, as he shares the impactful moments of significant weight loss and the profound influence of Dr. Jeffrey Veal of UCLA, whose innovative approaches to kidney transplantation and stem cell therapy are shaping the future of patient care. Our conversation traverses the emotional and practical terrains of life with a chronic illness, offering a window into the compassionate bonds that fortify those affected and the pioneering medical strides that hold promise for a life less burdened by medication.As we round off our exploration of Blake and Teresa's awe-inspiring journey, we're reminded of the broader implications of their experiences for the transplant community. We delve into the potential of medical advancements like stem cell therapy to transform lives and the altruism inherent in organ donation. Blake's involvement in cutting-edge treatment options underscores the relentless pursuit of a better future for those living with kidney diseases. The episode not only honors Blake's resilience but also serves as a clarion call for empathy, advocacy, and the transformative power of medical science. Join us to witness a story of extraordinary courage, the love that empowers it, and the innovations that might just change the transplant narrative forever.Dr. Jeffrey Veale, - UCLA KeepOnSharingReferal code - KOSSupport the showwww.CoachMikkiandFriends.comJoin my guests on my YouTube Channel

After attending ASN Kidney Week, Bluestar Principal Jeff Fineberg sits down with Dr. Pietro Canetta to talk all things IgA nephropathy (IgAN). After Dr. Canetta provides a brief summary of his IgAN lecture at Kidney Week, Emerging Therapeutic Options in IgA Nephropathy, the two discuss the Filspari (sparsentan) data presented from both the PROTECT study, in IgAN, the DUPLEX study, in FSGS. From there, Dr. Canetta opines on the value of surrogate endpoints in predicting the three D's of CKD: death, dialysis, and doubling of serum creatinine (SCr). Dr. Canetta briefly discusses Novartis' press release announcing the positive Phase II data with atrasentan, another ETA RA, before the conversation shifts to other drug classes and therapeutic targets, including SGLT2 inhibitors, and B-cell activation (i.e., APRIL/BAFF). Finally, Jeff asks Dr. Canetta about whether the recent advancements in IgAN are generalizable to other glomerular diseases, and what might be the determinants of this. Jump to specific topics in the conversation: 00:00 Recap + guest intro/bio + Kidney Week lecture summary 05:05 Filspari (sparsentan) trial results from PROTECT (IgAN) and DUPLEX (FSGS) 12:25 Value of surrogate endpoints in predicting three D's - death, dialysis, and doubling of SCr - in glomerular disease 19:55 Atrasentan press release 23:05 The "four-hit" hypothesis of IgAN pathogenesis and SGLT2i 26:10 B-cell activation (APRIL/BAFF) as a therapeutic approach in IgAN 31:55 Generalizability (and lack thereof) of therapeutic approaches to other glomerular diseases 37:25 Where to learn more Helpful links: PROTECT Study (Filspari/sparsentan in IgAN) DUPLEX Study (Filspari/sparsentan in FSGS) Novartis press release (atrasentan in IgAN) ENVISION Study (sibeprenlimab in IgAN) Columbia Glomerular Center For more information about Bluestar BioAdvisors, please visit our website.

Jennifer Cramer-Miller is a self-described incurable optimist. Her sense of humor, family, friends, and generous spirit keep her positive and grateful through her journey with FSGS and four kidney transplants. 

Synopsis: Keith Gottesdiener, MD, and Jeremy Duffield, MD, PhD, FRCP, are the President & CEO and CSO, respectively, of Prime Medicine. Prime Medicine was founded to bring the promise of gene editing to patients. They use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Keith and Jeremy discuss the arc of their careers and how they go to where they are today. They talk about the differences working in big pharma vs. a smaller biotech like Prime. They discuss the importance of companies investing in safety and what they've learned in terms of indication selection frameworks within the context of gene editing. Finally, they talk about their goal of engaging in partnerships down the road, and the importance of having transparency within their organization. Biography: Keith Gottesdiener, MD is President and Chief Executive Officer of Prime Medicine and has served as a member of our Board of Directors since July 2020. From October 2011 until March 2020, Dr. Gottesdiener served as the Chief Executive Officer and a director of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company that develops therapeutics in rare genetic obesity. During that time, Rhythm submitted a New Drug Application for setmelanotide in two indications, for which setmelanotide was subsequently approved. Dr. Gottesdiener received his B.A. from Harvard College and his M.D. from the University of Pennsylvania. He completed his residency and fellowship at the Brigham and Women's Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children's Hospital programs. After his fellowship, Dr. Gottesdiener did postdoctoral research in the laboratory of Dr. Jack Strominger at the Dana Farber Cancer Institute. He then joined the faculty as an assistant professor at Columbia University, where he started an independent research laboratory with NIH RO-1 funding, ending his academic career as Associate Clinical Professor of Medicine at the time he left to join Merck in 1995. Jeremy Duffield, MD, PhD, FRCP, is the Chief Scientific Officer of Prime Medicine. He has many years of drug discovery experience at Vertex Pharmaceuticals and Biogen Inc. preceded by a distinguished career in academic medicine. Dr. Duffield has held several leadership roles, with focus in the fields of human genetics, innate immunity and regenerative medicine. He served as Global Head of Human Biology at Vertex Pharmaceuticals and as Vice President of Business Development where he and his team played important roles in discovering and advancing candidates to clinical studies in rare diseases including cystic fibrosis, a1-antitrypsin deficiency, sickle cell disease, FSGS and muscular dystrophies. Several candidates are now approved therapies. He was instrumental in building Vertex Cell and Genetic Therapies. At Biogen, Dr. Duffield served as Senior Research Fellow and Vice President with responsibilities in early research programs, as joint Head of Innate Immunity and Regenerative Medicine therapeutic area, and as Head of the Biogen Post-Doctoral program. There he contributed to advancing integrin inhibitors, TNF superfamily inhibitors and IRAK inhibitors to clinical evaluation for pulmonary fibrosis and autoimmune diseases. Dr. Duffield received his B.A. and M.D. (B.M., B.Ch.) from Oxford University and a Ph.D. in Immunology from the University of Edinburgh in the laboratory of Sir John Savill.

Til tross for nok en tidligkamp vant Liverpool oppskriftsmessig mot Everton, og i toppen av Premier League er tett som bare det. Arve Vassbotten har med seg Torbjørn Flatin og Arild Skjæveland i «Liverpool.no Pausepraten».Dette er temaene: (Tidskodene kan avvike noe) 00:10: Er Tottenham «the real deal»? Er de en tittelutfordrer og hvilke andre lag vil kjempe i toppen denne sesongen. 06:34: Merseyside-derbyet: – Angrepskraften fikset det igjen, men Klopp leiter fortsatt etter enkelte brikker. 10:20: – Van Dijk tilbake som helt sjef. Spillere som trekkes frem og de som må skjerpe seg noe. 19:10: Høstens faste tema ser ut til å bli defensiv midtbane. Vi snakker igjen om Mac Allister og DM-rollen. 27:40: Er det noen grep dere mener Klopp bør gjøre de neste ukene nå med tanke på både taktikk og hvem han bruker? 36:15: Tanker om hva Klopp skal gjøre med høyrevingen når Afrikamesterskapet kommer i januar. 38:21: Damien Comolli var FSGs første sportsdirektør i Liverpool, i 2012 fikk han sparken, nå kommer han tilbake som styreformann i Toulouse. Hva slags minner og ettermæle etterlater Comolli fra tiden i Liverpool? Hosted on Acast. See acast.com/privacy for more information.

Clinical trials exist to help prevent, screen for, diagnose, or treat diseases and other health problems. Without them, we would not have new treatments or other advances in health and medicine. But how are the clinical trial endpoints, or the preferred outcomes of these trials determined? Today, Anthony Gucciardo NKF's Senior Vice President of Strategic Partnerships, Dr. Joseph Vassalotti, NKF's Chief Medical Officer, and Kent Bressler, a Patient advocate and FSGS patient, discuss this and more.   In this episode we heard from:  Dr. Joseph Vassalotti MD Dr. Vassalotti is the Chief Medical Officer of the National Kidney Foundation (NKF) and Clinical Professor of Medicine in the Division of Nephrology, at Icahn School of Medicine at Mount Sinai. At NKF, his major focus is implementation of evidence-based clinical practice guidelines in chronic kidney disease (CKD). He led collaborations to develop the Kidney Health Evaluation for Adults with Diabetes quality measure to improve evidenced based estimated glomerular filtration rate and albuminuria testing to guide detection, risk stratification and interventions proportional to risk in the U.S. He also served as PI for an AARP-funded Kidney Health Evaluation for Adults with Diabetes to analyze quality measure satisfaction with detection, evidenced-based therapies and health equity. Currently, he serves as Principal Investigator for the Kidney Score Platform, an NKF educational project funded by the Veterans Administration Center for Innovation to improve awareness and education among Veterans with and at risk for CKD in the primary care setting. He is also a co-investigator for the Center for Disease Control and Prevention's CKD Surveillance Project. Dr. Vassalotti typically sees approximately 40 patients per week and has over 100 publications in peerreviewed journals. Anthony Gucciardo Anthony is responsible for forging and maintaining relations with key external stakeholders across a wide range of industries, to advance NKF's mission and objectives, along with those of its partner organizations.  Anthony oversees two national Corporate Development Teams, focused on securing revenue necessary to ensure NKF programmatic excellence and impact.  He has been with the Foundation since 2002. Prior to NKF, Anthony was a Hematopoietic Stem Cell Technologist at Memorial Sloan-Kettering Cancer Center in New York City, where he was responsible for processing autogeneic/allogeneic bone marrow and peripheral blood stem cells for transplantation. He holds a master's degree in Biochemistry from Columbia University. Kent Bressler Kent is a retired RN who was diagnosed with FSGS in 1984, and received a living donor transplant from his brother Kip in 1987. Kent is an active advocate for preemptive kidney transplant and has on the recommendation of NKF worked closely with the DoD and PCORI as a consumer peer reviewer. He is an NKF peer mentor and advocate who has collaborated on an editorial “Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of Chronic Kidney Disease,” published in AJKD in 2019. He will also be participating in the development of the new NKF Patient Network serving on the Data Input and Integration Committee. He has been an active hill advocate for the NKF for six years and was the proud recipient of the 2017 Richard K. Salick Advocacy Award. Kent is also an Army Veteran and retired from the Veterans administration as an RN. He is the co-founder of Kidney Solutions a not for profit program in Texas that assists patients and families in the transplant process and in finding a donor. He is currently an assistant team leader for Region 7. Kent and Cathy Bressler have been married for 50 years and their family consists of Gretchen and Todd Rossington and their son Colt and Celeste and Alex Brown and their children John Banks, Catherine and Alexis Brown.   Additional Resources:  Find Clinical Trials  Clinical Trial Q&A  Xenotransplantation Info    Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.  

Join Drs Matthew Sparks and Kirk Campbell as they dive into the murky waters of focal segmental glomerular sclerosis. How do you diagnose? How do you treat? Tune in to find out. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991604). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Chronic Kidney Disease (CKD) https://emedicine.medscape.com/article/238798-overview Focal Segmental Glomerulosclerosis https://emedicine.medscape.com/article/245915-overview Membranoproliferative Glomerulonephritis https://emedicine.medscape.com/article/240056-overview Membranous Glomerulonephritis https://emedicine.medscape.com/article/239799-overview Collapsing Focal Segmental Glomerulosclerosis in Viral Infections https://pubmed.ncbi.nlm.nih.gov/35095882/ Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis https://pubmed.ncbi.nlm.nih.gov/36644367/ Glomerular Diseases (GD) https://kdigo.org/guidelines/gd/ A Review of Podocyte Biology https://pubmed.ncbi.nlm.nih.gov/29852492/ APOL1 Nephropathy: From Genetics to Clinical Applications https://pubmed.ncbi.nlm.nih.gov/32616495/ A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis https://classic.clinicaltrials.gov/ct2/show/NCT05213624 Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/35518835/ Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/ Calcineurin Inhibitors in the Treatment of Primary Focal Segmental Glomerulosclerosis: A Protocol of Systematic Review and Meta-Analysis of Randomized Controlled Trials https://pubmed.ncbi.nlm.nih.gov/33530282/ Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease https://pubmed.ncbi.nlm.nih.gov/33186054/ IgA Nephropathy https://emedicine.medscape.com/article/239927-overview Impact of Diabetes on the Effects of Sodium Glucose Co-Transporter-2 Inhibitors on Kidney Outcomes: Collaborative Meta-Analysis of Large Placebo-Controlled Trials https://pubmed.ncbi.nlm.nih.gov/36351458/ African Trypanosomiasis (Sleeping Sickness) https://emedicine.medscape.com/article/228613-overview Lupus Nephritis https://emedicine.medscape.com/article/330369-overview Inaxaplin for Proteinuric Kidney Disease in Persons With Two APOL1 Variants https://pubmed.ncbi.nlm.nih.gov/36920755/ Phase 2/3 Adaptive Study of VX-147 in Adults and Adolescents With APOL1-Mediated Proteinuric Kidney Disease https://classic.clinicaltrials.gov/ct2/show/NCT05312879 Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development https://pubmed.ncbi.nlm.nih.gov/32604776/ Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease (JUSTICE) https://classic.clinicaltrials.gov/ct2/show/NCT05237388 APOL1 Long-Term Kidney Transplantation Outcomes Network (APOLLO) (APOLLO) https://classic.clinicaltrials.gov/ct2/show/NCT03615235 Nephrotic Syndrome Study Network (NEPTUNE) https://repository.niddk.nih.gov/studies/neptune/

On today's episode of Architectette we welcome Cristina Mazutis. Cristina has a background in graphic design and is the business development manager for Red Elephant, a Texas-based company that focuses on the design and production of architectural signage. We talk about: Cristina's upbringing in Colombia, her start in graphic design, and how her organizational and management skills helped her grow into her current role Why Red Elephant focuses on architectural signage and how they approach partnerships with developers and architects The unexpected start of the company- how founder Indu Sanka transitioned from working for Southwest Airlines to opening a signage company  Red Elephant's rebranding! We talk about the complexity of rebranding and how the company chose to change its name from FSGS to Red Elephant We end by chatting about a few of Cristina's favorite projects, like Pegasus Park, and all of the considerations that go into making sure a signage project is beautiful, functional, and code compliant NEW! WE ARE LOOKING FOR SPONSORS! Reach out at ⁠⁠https://www.architectette.com/sponsor⁠⁠. Links: Red Elephant Website: https://www.fsgsgraphics.com/ Pegasus Park: https://www.fsgsgraphics.com/portfolio/pegasus-park/ Architectette Podcast Website: ⁠⁠www.architectette.com⁠⁠ Connect with the pod on LinkedIn (⁠⁠https://www.linkedin.com/groups/12735000/⁠⁠), Instagram (⁠⁠@architectette⁠⁠), and TikTok (⁠⁠@architectette⁠⁠) JOIN OUR MAILING LIST! ⁠⁠⁠www.architectette.com⁠⁠ Support Architectette with a donation: ⁠⁠https://podcasters.spotify.com/pod/show/architectette/support⁠⁠ Music by ⁠⁠AlexGrohl⁠⁠ from ⁠⁠Pixabay⁠⁠. --- Support this podcast: https://podcasters.spotify.com/pod/show/architectette/support

Kent talks with Marc Coronel, another patient with Focal segmental glomerulosclerosis (FSGS). Mark offers his unique insight into the importance of being focused on taking care of yourself. He talks of his life on dialysis and then Transplant and living with FSGS. If you have questions regarding items discussed during this episode or would like more information about Kidney Solutions weekly Support Group, contact Kent at kent.bressler@kidneysolutions.org For more information about Kidney Solutions, visit us at www.kidneysolutions.org Host: Kent Bressler Producer: Jason Nunez

Steve Glover, Co-founder and CEO of ZyVersa Therapeutics, focuses on rare kidney diseases and diseases with an inflammation component. Inflammasomes, the first response in the innate immune system, create an inflammation cascade.  The ZyVersa approach targets multiple inflammasomes to address diseases caused by the malfunction of this response. Steve explains, "Inflammation drives a lot of different diseases. And as we get into this a little bit more today, it's everything from kidney disease such as rare diseases such as FSGS and Alport syndrome and diabetic kidney disease all have an inflammation component. And in addition to that, when you look at diseases like Alzheimer's or MS, or Parkinson's, they're inflammation driven as well. So there is a connection between the two disease classes." "I've been in the industry a long time, and every so often the industry finds a new interesting discovery, and inflammasomes are clearly one of those new discoveries. In fact, one of the things I talk about quite a bit is that ten years ago, there were about two or so publications that were available on inflammasomes. Now there are over 20,000 publications available on inflammasomes. And this whole concept of inflammation driving certain diseases has become an area of an immense amount of research and development of products that can inhibit the inflammation you don't want in the human body." "When inflammasomes go into overdrive and are left uninhibited, they can cause a lot of damage to organs and cells in the body. And so, for example, they drive a lot of different diseases, everything from cancers to diseases such as Parkinson's and Alzheimer's disease, and a whole host of CNS diseases, as well as non-CNS diseases, that are driven by this inflammasome activation. So it's really important to find a way to inhibit those cytokines by inhibiting the inflammasome." #ZyVersa $ZVSA #RareDisease #InflammatoryDiseases #KidneyDisease #RenalDisease #FSGS #FocalSegmentalGlomerulosclerosis #AlportSyndrome #DiabeticKidneyDisease #Inflammasomes   ZyVersa.com Listen to the podcast here

Steve Glover, Co-founder and CEO of ZyVersa Therapeutics, focuses on rare kidney diseases and diseases with an inflammation component. Inflammasomes, the first response in the innate immune system, create an inflammation cascade.  The ZyVersa approach targets multiple inflammasomes to address diseases caused by the malfunction of this response. Steve explains, "Inflammation drives a lot of different diseases. And as we get into this a little bit more today, it's everything from kidney disease such as rare diseases such as FSGS and Alport syndrome and diabetic kidney disease all have an inflammation component. And in addition to that, when you look at diseases like Alzheimer's or MS, or Parkinson's, they're inflammation driven as well. So there is a connection between the two disease classes." "I've been in the industry a long time, and every so often the industry finds a new interesting discovery, and inflammasomes are clearly one of those new discoveries. In fact, one of the things I talk about quite a bit is that ten years ago, there were about two or so publications that were available on inflammasomes. Now there are over 20,000 publications available on inflammasomes. And this whole concept of inflammation driving certain diseases has become an area of an immense amount of research and development of products that can inhibit the inflammation you don't want in the human body." "When inflammasomes go into overdrive and are left uninhibited, they can cause a lot of damage to organs and cells in the body. And so, for example, they drive a lot of different diseases, everything from cancers to diseases such as Parkinson's and Alzheimer's disease, and a whole host of CNS diseases, as well as non-CNS diseases, that are driven by this inflammasome activation. So it's really important to find a way to inhibit those cytokines by inhibiting the inflammasome." #ZyVersa $ZVSA #RareDisease #InflammatoryDiseases #KidneyDisease #RenalDisease #FSGS #FocalSegmentalGlomerulosclerosis #AlportSyndrome #DiabeticKidneyDisease #Inflammasomes   ZyVersa.com Download the transcript here

Dr. Jula Inrig is the Chief Medical Officer of Travere Therapeutics and is eager to find innovative treatments for rare kidney diseases, which can be challenging to diagnose and have limited therapeutic options. In clinical trials, their lead candidate, sparsentan, reduces proteinuria significantly in patients with IgA Nephropathy and focal segmental glomerulosclerosis (FSGS). Travere is working with the U.S. Preventive Task Force to encourage earlier diagnosis and screening for these often silent diseases. Jula explains, "We've mapped out a path to get therapies approved for trying to avoid really what is one of the most detrimental complications of kidney disease, which is kidney failure, where you essentially wind up on dialysis. This is a treatment option where patients need to go into a clinic and be hooked up to a machine which cleans their blood three times a week. Or the other option is transplantation. One of the things that we have worked on is a molecule called sparsentan to try and avoid kidney failure." "Sparsentan is an investigational product candidate. It is a single molecule that doesn't suppress the immune system, which I think for a lot of our patients that's very important. It blocks two hormones that are in the path of causing damage within the kidney. What we have found with sparsentan is it reduces the pressure within the kidney, and it causes some remodeling within the kidney that reduces leakage of protein. When you leak protein within your kidney, that causes the kidney to then not clear toxins and then ultimately to progress faster causing kidney failure." @TravereRare #TravereTherapeutics #RareDiseases #RareKidneyDisease #KidneyDisease #EarlyDiagnosis Travere.com Listen to the podcast here

Dr. Jula Inrig is the Chief Medical Officer of Travere Therapeutics and is eager to find innovative treatments for rare kidney diseases, which can be challenging to diagnose and have limited therapeutic options. In clinical trials, their lead candidate, sparsentan, reduces proteinuria significantly in patients with IgA Nephropathy and focal segmental glomerulosclerosis (FSGS). Travere is working with the U.S. Preventive Task Force to encourage earlier diagnosis and screening for these often silent diseases. Jula explains, "We've mapped out a path to get therapies approved for trying to avoid really what is one of the most detrimental complications of kidney disease, which is kidney failure, where you essentially wind up on dialysis. This is a treatment option where patients need to go into a clinic and be hooked up to a machine which cleans their blood three times a week. Or the other option is transplantation. One of the things that we have worked on is a molecule called sparsentan to try and avoid kidney failure." "Sparsentan is an investigational product candidate. It is a single molecule that doesn't suppress the immune system, which I think for a lot of our patients that's very important. It blocks two hormones that are in the path of causing damage within the kidney. What we have found with sparsentan is it reduces the pressure within the kidney, and it causes some remodeling within the kidney that reduces leakage of protein. When you leak protein within your kidney, that causes the kidney to then not clear toxins and then ultimately to progress faster causing kidney failure." @TravereRare #TravereTherapeutics #RareDiseases #RareKidneyDisease #KidneyDisease Travere.com Download the transcript here

Description: In 2021, a work group of international experts published an update to the 2012 iteration of this guideline. To do so they reviewed the latest evidence through a systematic literature review, with the aim of providing a useful resource for clinicians caring for individuals with glomerular disease through actionable recommendations. In this episode we speak to Dr Richard Glassock, member of the work group, to hear his insights on the key takeaways from the guideline, and what has changed in this iteration. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. Reference: KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100(4S):S1–S276. Disclosures: Dr Richard Glassock declares the following: Stock Ownership - Reata Pharmaceuticals Speakers Bureau - Aurinia Advisory Board - Alexion, Bio-Cryst, Novartis, Otsuka, RenaSight, Travere, Vertex Consultant - Alexion, Arrowhead, Aurinia, Bio-Cryst, Calliditas, Chinook, Equillium, Horizon Pharma, Ionis, Midornid, Nephro-Sys, Omeros, River3Renal, Therini Bio, Travere, Vera Pharmaceuticals Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors. This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. Discussion of Off-Label, Investigational or Experimental Drug Use: Corticosteroids are mentioned in the context of the treatment of FSGS. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.

Dr. Charlotte Jones-Burton is the Senior Vice President of Product Development and Strategy at Chinook Therapeutics, which is on a mission to change the course of kidney care by discovering and developing precision therapies to maintain kidney function in people who have rare, severe chronic kidney diseases. Charlotte explains, "Our lead clinical program is atrasentan, a highly potent and selective endothelin receptor inhibitor. We believe that it's going to be a best-in-class molecule that's going to target the endothelin pathway. And the condition for which we are developing it is IgA nephropathy. Now, IgA nephropathy is an autoimmune disease that attacks the kidneys, and it affects how our blood is filtered in the small blood vessels of the kidneys that I spoke about. And what happens with IgA nephropathy is that immune complexes can deposit in the kidney and really damage those filtering units inside the kidneys. And when this happens, individuals can have symptoms such as protein spilling into their kidneys. And we know that proteinuria, as we call that, is a strong risk factor for those who will then develop end-stage kidney disease, which means that they may need dialysis or a kidney transplantation to survive." "Now, we know that there are few treatments that are available, and that's why it's really important for patients to also ask the question if there are any clinical trials. And we at Chinook Therapeutics are enrolling patients into clinical trials who have IgA nephropathy. We also are enrolling patients into our AFFINITY clinical trial if they have FSGS, which is also a type of kidney disease, Alport syndrome, or diabetic kidney disease." #ChinookTherapeutics #KidneyDisease #ChronicKidneyDisease #Atrasentan #BIO1301 #PrecisionMedicine #Nephrology #ClinicalTrials #IGAN #RareDisease chinooktx.com Download the transcript here

Dr. Charlotte Jones-Burton is the Senior Vice President of Product Development and Strategy at Chinook Therapeutics, which is on a mission to change the course of kidney care by discovering and developing precision therapies to maintain kidney function in people who have rare, severe chronic kidney diseases. Charlotte explains, "Our lead clinical program is atrasentan, a highly potent and selective endothelin receptor inhibitor. We believe that it's going to be a best-in-class molecule that's going to target the endothelin pathway. And the condition for which we are developing it is IgA nephropathy. Now, IgA nephropathy is an autoimmune disease that attacks the kidneys, and it affects how our blood is filtered in the small blood vessels of the kidneys that I spoke about. And what happens with IgA nephropathy is that immune complexes can deposit in the kidney and really damage those filtering units inside the kidneys. And when this happens, individuals can have symptoms such as protein spilling into their kidneys. And we know that proteinuria, as we call that, is a strong risk factor for those who will then develop end-stage kidney disease, which means that they may need dialysis or a kidney transplantation to survive." "Now, we know that there are few treatments that are available, and that's why it's really important for patients to also ask the question if there are any clinical trials. And we at Chinook Therapeutics are enrolling patients into clinical trials who have IgA nephropathy. We also are enrolling patients into our AFFINITY clinical trial if they have FSGS, which is also a type of kidney disease, Alport syndrome, or diabetic kidney disease." #ChinookTherapeutics #KidneyDisease #ChronicKidneyDisease #Atrasentan #BIO1301 #PrecisionMedicine #Nephrology #ClinicalTrials #IGAN #RareDisease chinooktx.com Listen to the podcast here

NBA great Alonzo Mourning returned home from the Sydney Olympics after winning the gold medal feeling ill. He surprisingly was diagnosed shortly after with kidney disease. Scientists have discovered his type of kidney disease is linked to having genetic variants of the APOL1 gene – ones that 13% of people with African ancestry carry. Dr. Ogo Egbuna leads clinical development for the team researching APOL1-mediated kidney disease at Vertex where they're investigating a small molecule therapy to target its underlying cause.Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.  Featured guests:Alonzo Mourning is a retired NBA player, the Vice President, Player Programs for the Miami Heat, an advocate for kidney disease research, and a beneficiary of a kidney transplant.David Friedman is an Associate Professor of Medicine, Harvard Medical School and a Principal Investigator and Nephrologist at Beth Israel Deaconess Medical Center. He's researched and consulted for Vertex Pharmaceuticals.Janice Lea  is a Professor of Medicine and Clinical Director of Nephrology at Emory University School of Medicine.Ogo Egbuna is Vice President, Clinical Development at Vertex Pharmaceuticals Read more about Vertex's approach to targeting kidney disease.Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.  

Historically, treatment options for focal segmental glomerulosclerosis (FSGS) have been limited to high-dose corticosteroids or calcineurin inhibitors in those ineligible or intolerant to steroids. However, an increase in clinical trial activity in the field of kidney disease may carry hope for novel therapeutic options for FSGS. This is illustrated by the recent approval of dapagliflozin for chronic kidney disease. In this episode, Dr. Kirk Campbell offers his expert opinion into the potential clinical implications of current and investigational therapies, both now and in the future. Learning objective After listening to this podcast series, learners will be able to recall the potential clinical implications of current and investigational therapies for FSGS. References available here Disclosures Dr. Kirk Campbell declares the following financial relationships from the past 24 months: Consultant - ANI, Calliditas, Chinook, Travere Research/grant support - Vertex Liberum IME staff, ACHL staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors. This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labelling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labelled for the use under discussion. Funding: This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.

Next on the Jeff Crilley Show, you're going to meet one of the most successful entrepreneurs in the DFW area. She was recently named one of DBJ's 40 Under 40. In this episode Jeff sits down with Indu Sanka, MBA, CEO of First Signs Graphic Solutions (FSGS). For over 11 years, FSGS has been a leading manufacturer of large format graphics and custom business signs for DFW's growing commercial real estate and apartment housing industry. Visit FSGS' website: https://www.fsgsgraphics.com/

While FSGS was once thought to be a single disease entity, it is now understood to be a pattern of injury caused by diverse mechanisms, but classifying FSGS accurately can be challenging. In this episode, we provide an overview of these classifications and risk factors that can help stratify disease progression risk and assist with determining management approaches. To help understand how we can most effectively and accurately classify FSGS, we are joined by Professor An De Vriese, who is head of the Division of Nephrology and Infectious Disease at the AZ Sint-Jan hospital in Bruges, Belgium. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References: 1. De Vriese AS et al. Differentiating primary, genetic, and secondary FSGS in adults: A clinicopathologic approach. J Am Soc Nephrol 2018;29(3):759-774. 2. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100(4S):S1–S276. 3. Jacobs-Cachá C et al. Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers. Clin Kidney J 2020;14(2):482-491. 4. Friedman DJ & Pollak MR. APOL1 nephropathy: From genetics to clinical applications. CJASN, 2021;16(2):294-303. 5. Zee J et al. APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. Pediatric Nephrology. 2021;36(9):2747-2757. 6. Shabaka A et al. Focal segmental glomerulosclerosis: State-of-the-art and clinical perspective. Nephron 2020;144(9):413-427. Disclosures: Prof. An De Vriese has no disclosures to announce. Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.

CastSusan ThanabalasingamDana LarsenMythri ShankarSandy SureshReferencesNeal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 2017 Aug 17;377(7):644–57.Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine. 2019 Jun 13;380(24):2295–306.Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2020 Oct 8;383(15):1436–46.Joshi SS, Singh T, Newby DE, Singh J. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021 Jul 1;107(13):1032–8.Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015 Nov 26;373(22):2117–28.ScriptContributors: Susan Thalabalasingam, Mythri Shankar, Dana Larsen, Sandhya SureshHost (Susan):Hey everyone! Welcome to our episode of 2 truths and a lie, an NSMC podcast.Let's go over the ground rules.One at a time each member of our elite education panel will state two truths and one lie about Nephrology.This episode will focus specifically on SGLT2 inhibitors. The other panelist will then discuss which statement they think is The Lie.Our presenter will then educate us all on which statement is incorrect and why.So let's warm up our lie detectors.Let's meet our four players for today.I'm your host Susan Thanabalasingam and I'm a first year internal medicine resident at Queen's University in Kingston, Ontario, Canada. I'm really excited to be your host today and to have an amazing discussion with these wonderful women today! Our second panelist is Dr. Mythri Shankar from India. Hi Dr. Mythri, can you please introduce yourself?Mythri: Hello everyone. I am Dr. Mythri Shankar, Assistant Professor in Nephrology from Institute of Nephro-urology, Bengaluru, India.I am also the Associate Program Director of the NSMC. Glad to be here and I have no conflicts of interest to declare.Our third Panelist Dr. Dana Larsen from the United States of America! Hi Dr. Larsen, can you please introduce yourself? Dana: Hi all! I am Dana Larsen, a second year nephrology fellow at University of California, San Francisco and so grateful to get to be on this podcast with this great group today. I have no conflicts of interest in today's topics. Our fourth Panelist is Dr. Sandhya Suresh from India. Hi Dr. Suresh, can you please introduce yourself?Sandhya: Hi to all my fellow members of the 4th Pod, the Distal convoluted Pod and also… Hi to everyone listening to this podcast. I am Dr. Sandhya Suresh and I'm an early career nephrologist working in a medical college in Southern India. My only declaration here is that I am a flozinator who is continually amazed by everything that the SGLT inhibitors can do. Susan: Great, so let me start, I'll give you 3 statements. My statements all focus on the use of SGLT2i in the non-diabetic CKD setting, which is a cohort that merits special attention when discussing the benefits of SGLT2i use (Susan)SGLT-2 inhibitors are nephroprotective in diabetic and non-diabetic CKD (TRUE)SGLT2 inhibitors decrease proteinuria in non-diabetic CKD (TRUE)SGLT2 inhibitors are indicated for all etiologies of non-diabetic CKD (FALSE) Explanation for 1 → Statement 1 is TRUE. SGLT-2 inhibitors are in fact nephroprotective in BOTH diabetic and non-diabetic CKD. The CREDENCE trial was the first to specifically examine kidney outcomes in patients with diabetic, proteinuric CKD, and it demonstrated significant decrease in risk for kidney failure and cardiovascular events in patients treated with canagliflozin (Perkovic et al, 2019). As the effects were independent of glucose lowering effects, further studies have been conducted in the non-diabetic CKD setting. DAPA-CKD included patients with both diabetic and non-diabetic CKD and found that the use of dapagliflozin was associated with decreased risk of >= 50% decline in eGFR, ESKD or death from renal or cardiovascular causes (Heerspink et al, 2020). Explanation for 2 → Statement 2 is ALSO TRUE. We do in fact have compelling data that proteinuria is reduced with the use of SGLT2i in non-diabetic kidney disease. Pre-specified analyses from the DAPA-CKD trial demonstrated that dapagliflozin significantly reduced proteinuria in both diabetic and non-diabetic CKD, although the effect was larger in the diabetic subset. Because clinical outcomes were similar with dapagliflozin initiation between diabetic and non-diabetic patients, despite this difference in effect size on proteinuria, it has been postulated that the observed nephroprotection may not actually be related to reduction in proteinuria. Explanation for 3 → Statement 3 was the FALSE statement. In DAPA-CKD, included etiologies of non diabetic CKD were FSGS, minimal change disease, chronic pyelonephritis, chronic interstitial nephritis and hypertensive, IgA, membranous, and obstructive nephropathies. However, patients with lupus nephritis, polycystic kidney disease and vasculitis were excluded. The results of EMPA-Kidney are highly anticipated, in part as it includes a larger number of participants without diabetes, in particular those with glomerular disease, which will hopefully give us more answers about whether these patients will also benefit from SGLT2i initiation. EMPA-Kidney does however also exclude patients with PKD (The EMPA-KIDNEY Collaborative Group, 2022). That was fun, I can't wait to hear more from the rest of our panelists. Moving on to Dr. Mythri now, can you please give us your 2 truths and a lie?Mythri:SGLT2i are the initial therapy for T2DM (FALSE)SGLT2i are beneficial in heart failure with reduced ejection fraction as it reduces both preload and afterload (TRUE)SGLT2i are analogs of Phlorizin (TRUE)Explanation for 1. SGLT2i are not the initial therapy. Initial therapy consists of lifestyle modifications, diet and exercise (American diabetes association guidelines 2021).Explanation for 2. SGLT2 inhibitors promote osmotic diuresis and natriuresis in patients with and without diabetes, and thus may reduce preload. SGLT2 inhibitors may also have vascular effects (including improving endothelial function) that promote vasodilation and thus may also reduce afterload. It has also been postulated that SGLT2 inhibitors may improve myocardial metabolism and thus improve cardiac efficiency. SGLT2 inhibitors promote osmotic diuresis and natriuresis in patients with and without diabetes, and thus may reduce preload (Joshi et al, 2021).Explanation for 3:A natural compound, phlorizin, was isolated from apple trees in the early 1800s and for decades played an important role in diabetes and renal physiology research. The compound is poorly absorbed from the gastrointestinal tract and inhibits both SGLT1 (primarily found in the gastrointestinal tract) and SGLT2. Analogs of phlorizin have been developed that circumvent these two problems. These are the current SGLT2i (Atanasov et al, 2016).Susan: That was great Dr. Mythri, thank you, I feel like I learned so much! Moving on to Dr. Dana, can you give us your 2 truths and a lie?Dana:Awesome, thank you Susan! Alright, please identify the lie from among these statements all concerning potential SGLT2 side effects:SGLT2 inhibitors definitively increase the risk of vulvovaginal candidiasis and may increase the risk of urinary tract infections. (TRUE)SGLT2 inhibitors do not definitively increase risk of bladder cancers. (TRUE)SGLT2 inhibitors definitively increase risk for limb amputations. (FALSE)Do you think you have the answer!?! Let's take a closer look…My first statement, SGLT2 inhibitors definitely increase the risk of urinary tract infections and vulvovaginal candidiasis is TRUE. Multiple studies on SGLT2 inhibitors including a 2018 canagliflozin RCT and a 2013 dapagliflozin RCT have shown 2-4 fold increase in vulvovaginal candidiasis in 10-15% of patients on SGLT2 inhibitors compared with placebo (Neal et al, 2017). A 2019 meta-analysis of over 100 RCTs with SGLT2s compared with other anti-diabetic agents or placebo did NOT show an increase in risk of UTIs for SGLT2s as a group, though there was a signal for increased risk of UTIs specifically for dapagliflozin, mechanistically it is unclear why this would be the case (Donnan et al, 2019). At this time, where there is definitive increased risk of vulvovaginal candidiasis, increased risk of UTI is likely not something you need to counsel your patients on.Alright, moving on, our second statement, SGLT2 inhibitors do not definitely increase risk of bladder cancers is also TRUE. While few cases of bladder cancers have been diagnosed in patients taking dapagliflozin, half of these occurred within the first 6 months, which is thought to be too soon for tumorigenesis promotion by dapagliflozin itself. EMPA-REG trial did not find increased incidence of bladder cancer once event rates that occured within the first 6mo of drug therapy were removed (Kohler et al, 2017). Currently, the FDA recommends ongoing postmarketing surveillance And finally, moving on to our final statement which must be FALSE given the name of the game, the statement says SGLT2 inhibitors definitively increase risk for limb amputations. While the CANVAS program found that in the over 10,000 combined patients from their two major trials there was an increased risk of amputations 6.3 vs 3.4 per 1000 participants with hazard ratio 1.97, these amputations were primarily at the level of the toe or metatarsal, not the limb (Neal et al, 2017). Furthermore, there is ongoing discussion over true risk of amputation attributed to SGLT2 inhibitors as post hoc analysis of empa-reg and CREDENCE, the renal outcomes trial for canagliflozin, no association for increased risk of lower extremity amputation was found (Perkovic et al, 2019). While further investigation into the topic is warranted, we can rest assured that this is our FALSE statement on side effects of SGLT2-inhibitors. Susan: Wow Dana, thanks so much for those very important lessons on SGLT2i side effects, I certainly have a lot of take home points from your discussion! Perfect, now we'll move on to Dr. Sandhya. Please join me in welcoming her to give us our final set of 2 truths and a lie today.Sandhya:Thank you Susan. So here, I will be focussing my 2 truths and a lie on the cardioprotective effects of SGLT2 inhibitors. Without further ado, here are my 3 statements:Statement 1: Increased ketone body production is postulated as one of the mechanisms for the cardioprotective effects of SGLT2 inhibitors (TRUE)Statement 2: Glucose lowering effect and cardiovascular benefits both decline at lower GFRs (FALSE)Statement 3: Sotagliflozin in a combined SGLT2 and SGLT1 inhibitor which has demonstrated cardioprotective benefits (TRUE)Explanations for the above statements: Let me go through the explanation for each statement one by one.Statement 1 is true. The cardioprotective effects of SGLT2 inhibitors may be multifactorial. While they target the traditional cardiovascular risk factors through their glycosuric and natriuretic effects, it is also postulated that SGLT2 inhibitors improve the cardiac metabolism and bioenergetics. 90-95% of cardiac energy is derived from mitochondrial oxidative metabolism for which the predominant fuel is free fatty acids. In a diabetic heart, the metabolic flexibility in terms of substrate utilization is impaired and the myocardium becomes more dependent on free fatty acids as fuel leading to build up of free fatty acid intermediates which lead to lipotoxicity and myocardial dysfunction. SGLT2 inhibitors produce a starvation simulation with reduced insulin and higher glucagon levels which promotes lipolysis and ketogenesis. They also reduce the excretion of ketone bodies by reducing the GFR. These ketone bodies like beta hydroxybutyrate serve as an alternate super fuel for myocardial cells producing ATP more efficiently and help to preserve the mitochondrial integrity and these factors lead to improved cardiac efficiency (Joshi et al, 2021).Now coming to statement 2. The glucose lowering effect of SGLT2 inhibitors does decrease with declining GFRs because the magnitude of glucose excretion and consequently the HbA1c reduction is dependent on the filtered glucose load. This filtered glucose load is high in diabetic patients with normal GFR and reduced in patients with renal impairment thereby leading to reduction in the glucose lowering effect of SGLT2 inhibitors (Kelly et al, 2018). Conversely, the cardioprotective effects of this class of drugs seems to be remarkably preserved at lower GFRs as has been demonstrated in several trials. For example, in the EMPAREG OUTCOME trial, analysis of a subgroup of patients with prevalent kidney disease was done which included type 2 diabetic patients with established cardiovascular disease and an estimated GFR between 30-60 . There was significant reduction in the cardiovascular and all-cause mortality as well as hospitalization for heart failure in this subgroup and this effect was consistent across different categories of GFR (Wanner et al, 2017). So statement 2 is false.So by that logic statement 3 has to be a truth. We often talk about the 4 traditional flozins so I just wanted to throw in a statement about this new subclass within this class of agents. Sotagliflozin is an SGLT2 inhibitor which also inhibits the intestinal SGLT1 transporters. It was originally targeted for use in patients with type 1 diabetes mellitus with the hope that SGLT1 inhibition in the intestine could reduce postprandial hyperglycemia and improve overall glycemic control in these patients. Studies have also shown excellent efficacy for this purpose. However they also showed a higher incidence of Diabetic ketoacidosis episodes. 2 cardiovascular trials were conducted, both of which unfortunately, ended early as they lost funding sometime during the COVID pandemic. The SCORED trial included CKD patients and the SOLOIST-WHF trial included patients who had recently recovered from an episode of decompensated heart failure. I won't go into the strengths and limitations of these trials but they did show benefit in terms of cardiovascular endpoints in the sotagliflozin group compared to placebo (Bhatt et al, 2021; Bhat et al, 2021). The drug isn't commercially available as of now and is not FDA approved yet but it remains as a novel agent within the SGLT2i landscape.Susan (Conclusion by host):Amazing, thank you so much Dr. Sandhya! That was an enlightening discussion on cardioprotection with SGLT2i use. And this has been so much fun! I hope you've all found our conversation really helpful and informative - I certainly know that I have learned a lot from my colleagues today. I can't thank them enough for sharing their time and expertise with us. Be sure to tune in next time for more FOAMed nephrology education.

Welcome to PICU Doc On Call, a podcast dedicated to current and aspiring intensivists. I am Pradip Kamat. I am Rahul Damania, a current 3rd year pediatric critical care fellow. I am Kate Phelps- a second year pediatric critical care medicine. We come to you from Children's Healthcare of Atlanta Emory University School of Medicine. We are delighted to be joined by guest expert Dr Stephanie Jernigan Assistant Professor of Pediatric-Pediatric nephrology, Medical Director of the Pediatric Dialysis Program at Children's Healthcare of Atlanta. She is the Chief of Medicine and Campus Medical Director at Children's Healthcare of Atlanta, Egleston Campus. Her research interests include chronic kidney disease, and dialysis. She is on twitter @stephaniejern13 I will turn it over to Rahul to start with our patient case... A 3 year old previously healthy male presents with periorbital edema. Patient was initially seen by a pediatrician who prescribed anti-histamines for allergy. After no improvement in the eye swelling after a two week anti-histamine course, the patient was given a short course of steroids, which also did not improve his periorbital edema. The patient progressed to having abdominal distention and was prescribed miralax for constipation. Grandparents subsequently noticed worsening edema in his face, eyes, and feet. The patient subsequently had low urine output, low appetite and lack of energy patient was subsequently brought to an ED and labs were obtained. Grandparents denied any illness prior to presentation, fever, congestion, sore throat, cough, nausea, vomiting, gross hematuria, or diarrhea. In ED patient was noted to be hypertensive (Average systolic 135-highest 159mm HG), tachycardic (HR 130s-140s), breathing ~20-30 times per minute on RA with SpO2 92%. Admission weight was recorded at 16.5Kg. Physical exam showed periorbital edema, edema of ankles, there was mild abdominal distention (no tenderness and no hepatosplenomegaly), heart and lung exams were normal. There were no rashes on extremities. Labs at the time of transfer to the PICU: WBC 10 (62% neutrophils, 26% lymphocytes) Hgb 7.2, Hct 21, Platelets 276. BMP: Na 142/K 8.4/Cl 102/HCO3 19/BUN 173/creatinine 5.8. Serum phosphorus was 10.5, Total Ca 6.4 (ionized Ca= 3.4), Mag 2.0, albumin 2.6, AST/ALT were normal. An urine analysis showed: 1015, ph 7.5, urine protein 300 and rest negative. Chest radiograph revealed small bilateral pleural effusions. After initial stabilization of his hyperkalemia-patient was admitted to the PICU. PTH intact 295 (range 8.5-22pg/mL). Respiratory viral panel including for SARS-COV-2 was negative. C3 and C4 were normal. A nephrotic syndrome/FSGS genetic panel was sent. A renal US showed: bilateral echogenic kidneys and ascites (small volume). Pradip: Dr Phelps what are the salient features of the above case presented? Kate Phelps: This patient has a subacute illness characterized by edema, anemia, and proteinuria. His labs show that he has severe acute kidney injury with significantly elevated BUN and Creatinine, hyperkalemia, hyperphosphatemia, and hypocalemia. Rahul: Dr Jernigan welcome to PICU Doc on Call Podcast. Thanks Kate, Rahul and Pradip for inviting me to your podcast. This is a such a great way to provide education and it is my pleasure to come today to speak about one of my favorite topics, pediatric dialysis. I have no financial disclosures or conflicts of interest and am ready to get started. Rahul: Dr Jernigan as you get that call from the ED and then subsequently from the PCCM docs, as a nephrologists whats going on in your mind ? When I get the call from the outside hospital my first job is to make sure the patient is safe and stable for transfer to a tertiary care center. This includes concern about airway, breathing and level of alertness. From a renal standpoint, I am worried about elevated blood pressure, electrolyte abnormalities, in this case primarily the hyperkalemia, and fluid...

In this podcast, Dr. Kim Thielen, a nephrologist/kidney specialist with Minnesota Kidney Specialists joins us today to continue part 2 of our discussion on acute kidney injury, as we wade further "into the weeds"  discuss intrinsic renal disease. This episode will break down hallmark urinary findings and further subdivide intrinsic concerns into bland, nephrotic and nephritic, various causes, and treatment. Enjoy the podcast! Objectives:   Upon completion of this podcast, participants should be able to: State the 3 types of urinary analysis findings related to instrinic acute kidney injury. Describe etiology of presentation of each type of intrinsic acute kidney injury. CME credit is only offered to Ridgeview Providers & Allied Health Staff for this podcast activity. Complete and submit the online evaluation form, after viewing the activity.  Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at  rmccredentialing@ridgeviewmedical.org. To receive continuing education credit for this activity - click the link below, to complete the activity's evaluation. CME Evaluation (**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.)  DISCLOSURE ANNOUNCEMENT  The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview Medical Center & Clinics.  Any re-reproduction of any of the materials presented would be infringement of copyright laws.  It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker's outside interest may reflect a possible bias, either the exposition or the conclusions presented. Ridgeview's CME planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event. Thank-you for listening to the podcast. SHOW NOTES: *See the attachment for additional show information.  Intrinsic Kidney Injuries: Urinary analysis findings- Bland Urine: no protein - Nephrotic: protein - Nephritic: protein and blood Hallmark Urinary Findings: Casts - Tamm Horsfall Protein : Mucoprotein made by tubular epithelial cells that precipitate out and congeal    to form casts on whatever is in the cells at the time.  (i.e. RBCs, WBCs, tubular debris) Bland Urine States- Crystalline Induced Renal Injury: obstruction and infllamatory response       - Uric Acid Neuropathy (Most common)              - Cancers, lymphomas, etc.              - Drugs: acyclovir, methotrexate, protease inhibitors, etc.              - Toxins: Ethylene glycol - Bland Urine Disease states: results from injury to tubules, instertim or pre glomerular blodd vessels, not    the filters of the kidney       - Interstital Nephritis              - Hallmark: pyuria and WBC casts                      - Biopsy: inflammatory infiltrate              - Causes:  viral, PPIs, Adenover, mizalamin, etc., Checkpoint inhibitors       - Acute Tubular Necrosis              - Hallmark: tubular epithelial cell cast                      - Granular: (course or fine) diagnostic of ATN              - Biopsy: denuded dilated tubular cells              - Causes: #1: Ischemia;  toxins, drugs, contrast dye;  pigment injury. myoglobin              - What about contrast dye?                      - Categorized under ATN                      - Per Dr. Thielen, plays a role, but injury is not solely dependent on dye alone.       - Hepatorenal Syndrome: ischemic injury to the kidney due to unopposed vasocontstriction               - Ace inhibitors cause unopposed efferent vasoconstriction + nonsteroidals cause                 unposed afferent vasoconstriction = no glomerular perfusion pressure       - Multiple Myeloma              - Hallmark: Light chain cast nephropathy or myeloma kidney                      - Light chains precipitate  out causing obstruction, inflammatory response and causes                        tubular damage              - Presentation: older possibly with anemia, bone pain and elevated creatinine with a bland urine.              - Protein to creatinine ratio: + for protein (non albumin)              - Dipstick: (which measures for albumin and not light chains) will be negative for protein aka                 bland urine       - Hypertensive Nephrosclerosis              - Small vessel vascular disease                     - Blood vessels prematurely atherosclerosis causing glomerular drop out and scarring of the                        interstim       - Scleroderma                - Limited cutaneous systemic sclerosis                - Diffuse cutaneous systemic sclerosis: 60-80% have renal injury from disease state itself                           - FANA positive                           - Concern for Scleroderma Renal Crisis = medical emergency                                   - AKI, moderate to severe HTN and bland urine                                   - Uncontrolled accumulation of collage, thickens vascular walls, narrowing and renal                                       ischemia                          - Occurs in 10-15% of those with Diffuse Cutaneous Systemic sclerosis and happens early                              in disease                                     - Left untreated: renal failure in 1-2 months and death in 1 year                          - Treatment: ACE Inhibitor Nephrotic Urine States - Urine protein: albumin excretion greater than 3.5g in 24 hours - Nephrotic Syndrome:      - Present with 3 things (nephrotic range protein, hypoalbuminemia, peripheral edema)       - Hyperlipidemia: due to increased hepatic lipogenesis                - Increased risk of renal disease and arthroscleratic       - Venous thrombotic disease:                 - Loose proteins other than albumin and develop a hypercoagulale state                 - Renal and peripheral venous thrombosis      - Lipiduria (forms fatty casts,  looks like a latese cross under microscope)  -Pathophysiology or nephrotic syndrome    - Glomerular capillary wall           - 3 layers that work as a glomerular filtration and responsible in the filtration between blood and             urine                  - Fenestrated Capillary Enothelial cells (fenestrations allow plasma through to the basement                     membrane)                 - Glomerular Basement Membrane (maintains glomerular filtration barrier; negatively charged,                     repels albumin)                 - Epithelium: Podocytes (Have highly specialized foot processes that connect and form slit                     diaphragms; Slit diaphragm important for the efficient flow of small solute and water)          - Anything that messes with any of these layers: nephrotic proteinuria - Nephrotic Disease States:     - Biopsy: anyone with nephrotic proteinuria (besides diabetics)          1) Light microscopy: high overview          2) Immunofluorescens: looks for nephritic component and identif immunce complexes          3) Electron microscopy: (EM) helps look at the ultrastructure and better identify immune deposits    - Diabetic nephropathy           - Leading cause of kidney disease in U.S. and western society           - Responsible for 30-40% of all ESRD causes           - Hyperglycemia: produces inflammatory responses, oxidative stress, and injures the podocytes and             deposits that charge and affect the ability of the kidney to filter.     - Amyoidosis            - Organize into betapleted sheets and produce spikes of the capillary uniion and poke through the               GF membrane            - Easily identified by apple green birefringence on congo red            - Terminal illness            - Present with HTN, cardiac effects and elevated creatine  - Nephrotic Disease states based of histologic appearance      - Diagnosed by histologic appearance but does not determine the etiology      - Minimal Change Disease              - Fairly common              - Minimal change under light microscope              - EM: podocytes are abnormal, fused, no unique cell-cell junction              - Primary: Immune generated circulating facture;  alters the cytoskeleton of the podocytes       - Secondary               - Nonsteriodal - most common cause of secondary minimal change disease               - Gama interferon               - Hodgkin's lymphoma               - Allergy: 30% of minimal change have associate allergy (mechanism unknown)       - Presentation               - Sudden onset (days to weeks)               - Marked edema and hypoablbuminemia               - 60% have normal blood pressure,    82% have normal creatinine - Focal Segmental Glomerulosclerosis (FSGS) - primary and secondary         - Most common cause idopathic nephrotic syndrome in adults        - Primary glomerulonephritis in the US that causes ESRD        - Widespread podocyte injury     - Primary: circulating factor that messes with regulation of foot process and adhesion to the         glomerular basement membrane (afffect all podocytes)          - Present with nephrotic syndrome and rapid progression          - HTN and elevated creatinine    - Secondary: the visceral epithelial cells don't replicate          - Nephron loss or obesity or direct foot process injury          - Cannot replicate (podocytes), leads to decreased to podo denisty at specific areas (focal injury)          - 2/3 of all cases FSGS          - Present: with slowly increasing proteinuria and kidney impairment over time          - Causes: interferon, bisphosphonates, talc, anabolic steroids    - Genetics: gene mutations that encode for the slit diaphragms of the podocytes (affect all podocytes)            - Present in Childhood: full blown nephrotic and progress rapidly to ESRD Membranous Nephropathy - Most common cause of nephrotic syndrome in caucasion adults - 80% present with nephrotic but develops more slowly to ESRD - Primary: Major antigen identified      - antibody to trans-membrane receptor that is highly expressed on the glomerular podocyte - Secondary: Cancers (lung, breast, GI), Lupus, Thyroiditis, Hep B, Syphilis, Nonsteroidals, Monoclonal    Antibodies Nephritic Syndrome - Hematuria and proteinuria    - Hematuria: blood from kidney or outside the kidney             - Outside the kidney: look the same             - Inside the kidney: dysmorphic red cells    - Present:             - Renal impairment for days to weeks             - Edmatous, HTN and look critically ill              - Vasculitis, sinusitis, oral ulcers             - Pulmonary renal syndrome: short of breath or hemoptysis             - Skin changes: bruising , bleeding, purpura             - Myalgias and arthritis     - Urine:             - Hallmark: red blood cell casts (polymorphic red cells)             - dipstick + for blood             - elevated proteinuria    - Biopsy: nephritic and + urine Nephritic Disease States (based on immunofluorescence staining) - Pauci Immune Disease         - Ankle vasculitis, common         - A paucity (little amount) of immune complexes         - See black on imaging         - Lab work: check on ANCA and peripheral eosinophils - Anti-GBM Disease         - Renal limited, or classic pulmonary renal: Good Pasture's          - linear staining of the glomerular basement with anti IGG (looks like a ribbon on a package)          - Treat with cytotoxic agents - Immune Complex          - Starry sky pattern          - Glomerulus looks dotted with stars                - Stars = immune complex definition          - Diseases:  Lupus (FANA), Post Infectious GN, Membranous Proliferative GN  - IGA Nephropathy           - Most common cause of glomerulonephritis in the world          - Presentation:                 - Peak incidence is the 2nd and 3rd decades of life                - 40-50% gross hematuria with upper respiratory and GI illness          - Risk Factors for Progression:                - younger age or hypertension at time of presentation                - > 1g proteinuria                - Elevated creatinine at time of presentation Thanks for listening.

#kidneyfailure #fsgs #kidneyfighter

While focal segmental glomerulosclerosis (FSGS) is rare overall, it is one of the most common glomerular diseases on Europe, North America and Latin America. Rather than being a specific disease entity, it is a pattern of injury that takes various forms that, together with the clinical presentation, have important implications for treatment and prognosis. Join Dr Sanjeev Sethi, pathologist at the Mayo Clinic, Rochester, Minnesota, USA, for an overview of our current understanding of how FSGS develops and presents. By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References: 1. McGrogan A, Franssen CF, de Vries CS: The incidence of primary glomerulonephritis worldwide: A systematic review of the literature. Nephrol Dial Transplant 26: 414–430, 2011 2. Sim JJ, Batech M, Hever A, Harrison TN, Avelar T, Kanter MH, Jacobsen SJ. Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000-2011 Among a Racially and Ethnically Diverse US Population. Am J Kidney Dis. 2016 Oct;68(4):533-544. 3. Rosenberg AZ, Koop JB. Focal segmental glomerulosclerosis. Clin J Am SOc Nephrol. 2017;12(3): 502-517. 4. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–S276. 5. Lepori N, Zand L, Sethi S, Fernandez-Juarez G, Fervenza F. Clinical and pathological phenotype of genetic casues of focal segmental glomerulosclerosis in adults. Clinical Kidney J. 2018;11 (2): 179-190. Disclosures: Dr Sanjeev Sethi has no relevant disclosures to report at this time. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME and validated by an independent steering committee; Travere Therapeutics has had no influence on the content of this education.

Tarik lost 45lbs, reversed pre-diabetes, high blood pressure and most importantly is healing his Focal Segmental Glomerulosclerosis (FSGS). Focal segmental glomerulosclerosis (FSGS) is a rare disease that affects the filters in your kidneys. When these filters are scarred, they are unable to filter your blood, which can lead to kidney damage and failure. Treatment for FSGS focuses on treating the symptoms and preventing any additional scarring. His doctors said they had never seen such improvement and to keep doing what he's doing. He hopes to be off medications very soon. Tarik is also finally strong enough to pursue his fitness goals so check out his workouts on his YouTube channel.

Today's hot topic is plant-based diets. For some kidney patients, eating more plant-based foods may help prevent and slow the progression of chronic kidney disease. But what exactly does a plant-based diet entail and how do you know if this diet is right for you? In this episode, you will hear from:   Brittany Sparks, RDN, CSR: Brittany Sparks is a registered dietician and board-certified specialist in renal nutrition. Her private practice focuses heavily in helping those with chronic kidney disease. She provides evidenced based medical nutrition therapy and enjoys speaking nationally on nutrition-related topics. She also creates recipes and teaches how to follow through with nutrition recommendations in the kitchen.   Eric Singer: Eric Singer was diagnosed with focal segmental glomerulosclerosis (FSGS) in 2007 and currently advocates for whole food, plant-based diets.   Additional resources: Finding a dietitian - https://bit.ly/378LNtG Finding a dietitian - https://bit.ly/3xcfa8Q KDOQI guidelines: https://bit.ly/3rIxxRC Plant-based Recipes: https://bit.ly/3ycxNLt More plant-based info: https://bit.ly/3BUr8aP

On this weeks episode I was joined by a long time friend Malcom Valdivia, owner of Dead Guy Designs. Malcolm has a truly inspiring story on how he has attacked his rare autoimmune disease, FSGS, and his two kidney transplants. This man is a warrior and has helped my personally put things in life into perspective. This is an episode you won't want to miss.

Lollar Pickups Blackface Strat Pickups Demo & Giveaway - In this video I switch out the original pickups from a Squier Strat and replace them with the Lollar Pickups Blackface Strat Pickups. As mentioned in the video, I will be giving away: - A Squier Strat Guitar setup by pro luthiers at Guitar OR in Calgary - Lollar Pickups Blackface Strat set - Custom Picks from Tree Picks (who will also plant some trees as well) Click this link to enter the competition: https://fretsuccess.com/lollar-blackface-giveaway . Competition will end on 23 Jul 2021 at 12pm MST. Check them out the pickups here: https://www.lollarguitars.com/lollar-stratocaster-pickups/strat-blackface Watch my interview with Jason Lollar here: https://youtu.be/Y3tS43_LsbM Listen to the podcast version by searching for the Fret Success Guitar Show on your favourite player. #lollarpickups #custompickups #stratpickups #stratocaster #guitargear2021 #pickups #FSGS #fretsuccess #guitarteacher #calgary #guitartone #customguitars #treepicks --- Support this podcast: https://anchor.fm/the-fret-success-guitar-show/support

(2:06) Feeling alone and reaching out,…(2:55) The events leading up to diagnosis…(6:11) “When I was in the middle of it, I just felt so uncomfortable. I felt so sick. I was so tired, and I felt so grateful that I was older and able to talk when I got diagnosed because hearing it was a kid's disease… I couldn't imagine going through it when I was younger, and I couldn't vocalize to other people how I felt.”(8:24) Swelling, school, Covid, and a supportive family…(11:05) Great doctors and great teachers…(13:23) “My answer would be my kidneys hate me or my kidneys are misbehaving just cause they're doing their own thing and it was easier sometimes not getting all the way into it.”(16:55) Plans after graduation…(18:30) “I became so interested in how intertwined the body is, how one little thing kind of effects everything else. And that just fascinated me. So I was like, I get to learn more about that. I get to help people, which I just love doing.”(19:41) Horseback riding…(21:17) Finding the right meds to get to healthy kidney function…(27:18) Losing a horse…(29:31) Figuring out correct dosing routines…(37:25) Talking about blood draws and IVs…(41:53) “The attending that was on my case would make a list in the morning of things to do. So, I would stay motivated. They offered to discharge me when I was really sad. When my horse passed away, they were like, you can go home and you can just come back in a few days.”(44:56) Boston Children's Hospital…(47:09) What were things that made school easier and plans for college…(49:58) Advice from Mikaela… “You need to reach out. You need to talk to people. You're going to collapse if you try to carry this all on your own.”

In this episode, we talk about the NKF Patient Network, an online registry for kidney patients at any stage of kidney disease. This network is an exciting new and easy way to for patients to be part of the effort to improve the lives of people affected by kidney disease everywhere.    In this episode, you will hear from:   Dr. Kerry Willis: Dr. Kerry Willis is Chief Scientific Officer at the National Kidney Foundation and co-developer of the Patient Network. Dr. Willis received her PhD in Molecular Genetics from New York University Medical Center and has been with NKF since 1998. She founded NKF's Medical Activities division and made it a priority to identify and apply the best science available to improve kidney disease patient care and outcomes.   Dr. Lesley Inker: Lesley A. Inker, MD, MS is a nephrologist who serves as Director of the Kidney and Blood Pressure Center and Director of the Kidney Function and Evaluation Center at Tufts Medical Center. She is also chair of the NKF Patient Network Steering Committee. Dr. Inker's research has established her as an expert in the implementation of estimated glomerular filtration rate by clinical laboratories, as well as an expert in estimating and measuring kidney function.   Dr. Alex Chang: Dr. Alexander Chang is a nephrologist, assistant professor of Clinical Research and co-director of the Kidney Health Research Institute at Geisinger. He is engaged in research dedicated to preventing and delaying CKD progression and its complications. His research areas include interventional studies focused on improving lifestyle behaviors in patients with hypertension and patients with early CKD; using observational data from Geisinger and other large cohorts to identify potential avenues to improve management of CKD and hypertension; and health system interventions to improve early recognition and optimized management of early kidney disease. Dr. Alex Chang also serves as NKF Patient Network PI for Geisinger site.   Curtis Warfield: Curtis Warfield is a kidney patient and patient stakeholder on the Patient Network Advisory Committee. In 2012 he was diagnosed with Stage 3 Chronic Kidney Disease (CKD) due to FSGS. In 2016, he received a kidney from his daughter's college sorority sister. Curtis, a passionate advocate for CKD, organ donation and living donors provides peer counseling with the NKF Peer Program. He also serves as member of NKF's Kidney Advocacy Committee, where he advocates with members of Congress for kidney and organ donor issues.   Cari Maxwell: Cari Maxwell is a kidney patient and patient stakeholder on the Patient Network Advisory Committee.  She was diagnosed with Autosomal Dominant Polycystic Kidney Disease in 1989 and has been an active supporter of the National Kidney Foundation. She hopes that through her commitment to the awareness of chronic kidney diseases, others will take an active role in their health journey through early detection, healthy choices, and becoming a strong voice themselves in advocating for those that cannot.   Learn more about the NKF Patient Network by visiting www.kidney.org/nkfpatientnetwork.

Join us as we interview Gretchen Jackson and she will share her incredible story with battling FSGS, kidney disease, doing home peritoneal dialysis and more! We will also advocate for a living kidney donor! Don't miss it! https://m.facebook.com/Kidney4gretchen/ https://instagram.com/kid.neyforgretchen?igshid=9rsgxyeyp4kf

(2:30) How Nicki got connected to the NSF Peer Team and the power of a community…(5:11) Nicki's nephrotic syndrome journey begins…(9:57) A Google search reveals scary possibilities…(11:32) A trip that revealed so much…(14:07) “So I was wearing these compression socks, and I was in the middle of a crowded subway with all of my master's program students, and I started feeling faint.”(17:37) Shock and then grieving sets in…(19:48) “Nephrotic syndrome was a wake-up call to healing from that persona and that lifestyle of thinking I always needed to achieve, always needed to be perfect, always needed to be president of everything and working on something and never take a break. And I think that's what stressed my body out a lot in the first place.”(20:46) The year after graduation and the experience with Prednisone…(24:52) No formal diagnosis…(26:27) An autoimmune component and a glimmer of hope…(29:47) Several medications, side effects, and a strong desire to reach remission…(30:44) A link between gut health and nephrotic syndrome…(33:25) Finding an incredible nephrologist who is willing to look at all options…(35:40) It takes the right team effort…(38:16) “I went from sitting on the couch all day to now functioning, like a normal person, having energy to go above and beyond during my days and achieve so many things that I never thought I could do.”(40:33) Mushrooms, coffee, and lifestyle…(46:34) “What else can be addressed to lessen inflammation, to make me have energy and feel better and have a good quality of life through this diagnosis?”(50:20) A trifecta for healing…(51:48) The personal side of things…(56:39) “It's an easy thing to do to let your life become nephrotic syndrome for a little while.” Andi, Jeremy, and Nicki comparing experiences…(59:45) Family support, trust, and rebirth…(1:02:52) Future goals and a piece of advice...To reach out to Nicki:Instagram @nephnicki  Blog nephnicki.comOther resources mentioned by NickiMy root cause practitioner is Emily Morrow: @emilymorrow on Insta Her website is theemilymorrow.comShe is currently filled with individual clients but works with women in her group program called Root Cause Formula that accepts applications. She also offers courses in blood chemistry and lots of free resources to guide one's journey. She is certified as an FNTP (Functional Nutritional Therapy Practitioner) and IHP (Integrative Health Practitioner).  My life coach is Elise Dean, and she coaches with Blush Life Coaching: @joinblush on Insta and joinblush.comThe service was created by Kali Rogers, Founder & CEO and a life coach, and Elise works alongside Kali as Creative Director and Senior Life Coach. While the team is comprised of women, I believe they will coach anyone! Part of their mission is to promote affordable coaching/mental health options (I could see it as a great resource for the Moms out there, in addition to patients!) 

In this short welcome episode, you will meet our hosts, Jon Rankin and Bryan Green, and learn more about what to expect in Season 1 of Fueling the Pursuit.Hosts:Jon Rankin - gobemore.co | @chasejonrankinBryan Green - maketheleapbook.com | @maketheleapbookPresented By:UCAN - ucan.co | @genucanYour Personal Best Awaits

Jarin Winterhalt | Guitar Repair Luthier - Guitar O.R. Calgary. It's not every day that you get to sit down with someone who has an impact on so many guitars on an everyday basis. We can sometimes neglect our guitars and even not know how to make them perform their best. Jarin Winterhalt has figured this out over his many years in the world of guitar repair and maintenance Jarin is a guitar repair luthier and we talked about his career so far, interesting guitars he's worked on and tips for things to watch out for. Watch the full interview. Check Out Jarin's website for more information: www.guitaror.ca #guitar #guitarlessons #jarinwinterfelt #guitarrepair #FSGS #fretsuccess #guitarteacher #calgary #guitartone --- Support this podcast: https://anchor.fm/the-fret-success-guitar-show/support

“These are just stories we're sharing, but you know, they all could triggera thought that maybe a parent might then be able to go follow up on andask a provider about...”—Andi CallawayIn this episode of The Nephrotic Syndrome Foundation podcast, we give youa glimpse into our vision and the “Why” behind our efforts. We're “setting thestage” for the many future stories you'll hear.We believe there are many warriors in the nephrotic syndrome world—frompatients, to parents, siblings, and providers—each with wisdom to share.Show Notes(3:25) Andi and Jeremy sharing what it feels like to share their own stories...(6:53) “I think that's one of our big goals of the podcast, is just to reallybring people together and show that there are so many things that we'veall had to go through.” Finding unity in shared experiences...(11:27) Reflecting back and being in the trenches—both contribute value.(15:04) “When you're having a great month, you don't need to tap into this.Go enjoy your month.” A podcast is a resource that can meet you whereyou're at.(18:43) Cynthia's inspiring journey...(21:34) Wilson's and Jeremy's experiences of not wanting one moreprocedure.(25:53) A shoutout to Dr. Orloff and Jon Rankin...(29:01) The Just One Challenge and how it fits into the nephrotic community...(32:27) “When I say that they are warriors, I believe it to the core of mybeing.”(35:22) What's the vision for the podcast six months and two years from now?(39:37) Getting something you believe in off the ground—chatting about thechallenges of starting the podcast.(43:10) Flashbacks, PTSD, and self-care...(47:22) All the types of guests...(59:55) Ways to get involved...